| The medicinal chemist’s toolbox: an analysis of reactions used in the pursuit of drug candidates SD Roughley, AM Jordan Journal of medicinal chemistry 54 (10), 3451-3479, 2011 | 2416 | 2011 |
| Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle A Jordan, JA Hadfield, NJ Lawrence, AT McGown Medicinal research reviews 18 (4), 259-296, 1998 | 918 | 1998 |
| The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells WJ Harris, X Huang, JT Lynch, GJ Spencer, JR Hitchin, Y Li, F Ciceri, ... Cancer cell 21 (4), 473-487, 2012 | 640 | 2012 |
| 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer PA Brough, W Aherne, X Barril, J Borgognoni, K Boxall, JE Cansfield, ... Journal of medicinal chemistry 51 (2), 196-218, 2008 | 506 | 2008 |
| Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study DG Rothwell, M Ayub, N Cook, F Thistlethwaite, L Carter, E Dean, N Smith, ... Nature medicine 25 (5), 738-743, 2019 | 235 | 2019 |
| Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular … PA Brough, X Barril, J Borgognoni, P Chene, NGM Davies, B Davis, ... Journal of medicinal chemistry 52 (15), 4794-4809, 2009 | 190 | 2009 |
| Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds N Baurin, R Baker, C Richardson, I Chen, N Foloppe, A Potter, A Jordan, ... Journal of chemical information and computer sciences 44 (2), 643-651, 2004 | 175 | 2004 |
| Fragment-based hit identification: thinking in 3D AD Morley, A Pugliese, K Birchall, J Bower, P Brennan, N Brown, ... Drug Discovery Today 18 (23-24), 1221-1227, 2013 | 174 | 2013 |
| Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia A Maiques-Diaz, GJ Spencer, JT Lynch, F Ciceri, EL Williams, ... Cell reports 22 (13), 3641-3659, 2018 | 172 | 2018 |
| Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date DP Mould, AE McGonagle, DH Wiseman, EL Williams, AM Jordan Medicinal research reviews 35 (3), 586-618, 2015 | 168 | 2015 |
| First-in-class chemical probes against poly (ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to olaparib DI James, KM Smith, AM Jordan, EE Fairweather, LA Griffiths, ... ACS chemical biology 11 (11), 3179-3190, 2016 | 127 | 2016 |
| Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines RJ Gillespie, SJ Bamford, R Botting, M Comer, S Denny, S Gaur, M Griffin, ... Journal of medicinal chemistry 52 (1), 33-47, 2009 | 119 | 2009 |
| 4-Amino derivatives of the Hsp90 inhibitor CCT018159 X Barril, MC Beswick, A Collier, MJ Drysdale, BW Dymock, A Fink, K Grant, ... Bioorganic & medicinal chemistry letters 16 (9), 2543-2548, 2006 | 119 | 2006 |
| Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia MB Pappalardi, K Keenan, M Cockerill, WA Kellner, A Stowell, C Sherk, ... Nature cancer 2 (10), 1002-1017, 2021 | 115 | 2021 |
| DNA replication vulnerabilities render ovarian cancer cells sensitive to poly (ADP-ribose) glycohydrolase inhibitors N Pillay, A Tighe, L Nelson, S Littler, C Coulson-Gilmer, N Bah, A Golder, ... Cancer Cell 35 (3), 519-533. e8, 2019 | 97 | 2019 |
| Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo [3, 4-d] pyrimidines, pyrrolo [2, 3-d] pyrimidines and 6-arylpurines RJ Gillespie, IA Cliffe, CE Dawson, CT Dourish, S Gaur, AM Jordan, ... Bioorganic & medicinal chemistry letters 18 (9), 2924-2929, 2008 | 82 | 2008 |
| Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments JR Hitchin, J Blagg, R Burke, S Burns, MJ Cockerill, EE Fairweather, ... MedChemComm 4 (11), 1513-1522, 2013 | 79 | 2013 |
| Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma AM Jordan, TH Khan, H Malkin, HMI Osborn, A Photiou, PA Riley Bioorganic & medicinal chemistry 9 (6), 1549-1558, 2001 | 77 | 2001 |
| Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II A Raoof, P Depledge, NM Hamilton, NS Hamilton, JR Hitchin, GV Hopkins, ... Journal of medicinal chemistry 56 (16), 6352-6370, 2013 | 73 | 2013 |
| Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma AM Jordan, TH Khan, HMI Osborn, A Photiou, PA Riley Bioorganic & medicinal chemistry 7 (9), 1775-1780, 1999 | 73 | 1999 |
Ian WaddellCSO, Cumulus OncologyE-mail megerősítve itt: cumulusoncology.com
